Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression.


Administration of high-dose interleukin-2 (HDIL-2) has durable antitumor effects in 5% to 10% of patients with melanoma and renal cell carcinoma. However, treatment is often limited by side effects, including reversible, multiorgan dysfunction characterized by a cytokine-induced systemic autophagic syndrome. Here, we hypothesized that the autophagy… (More)
DOI: 10.1158/0008-5472.CAN-12-0320


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics